INONZA 1 mg INONZA contains Inotuzumab Ozogamicin, a CD22-directed antibody-drug conjugate (ADC) composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide. Upon binding to CD22 receptors on B-lymphoid cells, the conjugate is internalized into the cell, releasing calicheamicin via hydrolytic cleavage. The released calicheamicin induces double-stranded DNA breaks, leading to cell cycle arrest and apoptotic cell death. It is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).